دورية أكاديمية

Elevated levels of DNA methylation at the OPRM1 promoter region in men with opioid use disorder.

التفاصيل البيبلوغرافية
العنوان: Elevated levels of DNA methylation at the OPRM1 promoter region in men with opioid use disorder.
المؤلفون: Ebrahimi, Ghasem, Asadikaram, Gholamreza, Akbari, Hamed, Nematollahi, Mohammad Hadi, Abolhassani, Moslem, Shahabinejad, Gholamabbas, Khodadadnejad, Leyla, Hashemi, Mohammad
المصدر: American Journal of Drug & Alcohol Abuse; 2018, Vol. 44 Issue 2, p193-199, 7p
مصطلحات موضوعية: OPIUM abuse, DNA methylation, ADDICTIONS, OPIUM, PHYSIOLOGY, PREVENTION, THERAPEUTICS, CELL receptors, DISEASE susceptibility, GENES, SUBSTANCE abuse, CASE-control method
مستخلص: Background: The mu-opioid receptor, encoded by mu-opioid receptor gene (OPRM1), has an important role in the development of addiction to opioids. Its aberrant reduction on the cell membrane is responsible, at least in part, for tolerance and physical dependence.Objectives: The present study was designed to identify the relationship between opium consumption and epigenetic mechanisms involved in opium addiction.Methods: Genomic DNA was extracted from the peripheral blood of 66 men with opium use disorder and 57 healthy men as a control group. Genomic DNAs were treated with sodium bisulfite to convert the un-methylated cytosine to uracil, while methylated cytosine remained unaffected. Nested methylation-specific PCR (MSP) was used for analyses of region 1 (R1) and region 2 (R2) of the OPRM1 promoter DNA methylation.Results: All participants were 19-56 years old, and there was no significant difference in the mean age of both groups (P = 0.082). After Bonferroni correction, results showed that the DNA methylation status significantly increased the risk of opium addiction in the R2 region compared with un-methylation status (OR = 3.80, 95%CI = 1.77-8.17, P = 0.001). However, we found no significant difference in the R1 region DNA methylation between case and control groups (21.2% and 21.1%, respectively) (P = 1).Conclusion: Our findings demonstrated DNA hypermethylation of the R2 region of the OPRM1 promoter in leukocytes of opium use disorder. In peripheral tissues such as blood, changes of epigenetic endpoints with substance use can be considered as potentially clinically useful biomarkers in identifying individuals who may warrant further diagnostic assessment of a substance use disorder. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00952990
DOI:10.1080/00952990.2016.1275659